- Home
- DSGN vs ARL Comparison
DSGN vs ARL Comparison
Compare DSGN & ARL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- ARL
- Stock Information
- Founded
- DSGN 2017
- ARL 1999
- Country
- DSGN United States
- ARL United States
- Employees
- DSGN N/A
- ARL N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- ARL Building operators
- Sector
- DSGN Health Care
- ARL Real Estate
- Exchange
- DSGN Nasdaq
- ARL Nasdaq
- Market Cap
- DSGN 208.9M
- ARL 233.2M
- IPO Year
- DSGN 2021
- ARL N/A
- Fundamental
- Price
- DSGN $3.93
- ARL $14.15
- Analyst Decision
- DSGN Hold
- ARL
- Analyst Count
- DSGN 1
- ARL 0
- Target Price
- DSGN $4.00
- ARL N/A
- AVG Volume (30 Days)
- DSGN 101.8K
- ARL 3.8K
- Earning Date
- DSGN 08-04-2025
- ARL 08-07-2025
- Dividend Yield
- DSGN N/A
- ARL N/A
- EPS Growth
- DSGN N/A
- ARL N/A
- EPS
- DSGN N/A
- ARL N/A
- Revenue
- DSGN N/A
- ARL $48,234,000.00
- Revenue This Year
- DSGN N/A
- ARL N/A
- Revenue Next Year
- DSGN N/A
- ARL N/A
- P/E Ratio
- DSGN N/A
- ARL N/A
- Revenue Growth
- DSGN N/A
- ARL N/A
- 52 Week Low
- DSGN $2.60
- ARL $9.43
- 52 Week High
- DSGN $7.77
- ARL $22.77
- Technical
- Relative Strength Index (RSI)
- DSGN 53.95
- ARL 48.78
- Support Level
- DSGN $3.84
- ARL $13.96
- Resistance Level
- DSGN $4.10
- ARL $15.15
- Average True Range (ATR)
- DSGN 0.26
- ARL 0.62
- MACD
- DSGN 0.04
- ARL -0.07
- Stochastic Oscillator
- DSGN 73.86
- ARL 37.35
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About ARL American Realty Investors Inc.
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.